Compounds > fenofibrate
Page last updated: 2024-10-27

fenofibrate and AIDS Seroconversion

fenofibrate has been researched along with AIDS Seroconversion in 2 studies

Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE

Research Excerpts

ExcerptRelevanceReference
"A combination of fenofibrate and niacin with low-saturated-fat D/E is effective and safe in increasing HDL-C, decreasing non-HDL-C and hypertriglyceridemia, and ameliorating hypoadiponectinemia in patients with HIV/ART-associated dyslipidemia."9.15Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. ( Balasubramanyam, A; Ballantyne, CM; Clark, P; Coraza, I; Cuevas-Sanchez, E; Giordano, TP; Iyer, D; Kamble, S; Patel, P; Pownall, HJ; Scott, LW; Sekhar, RV; Smith, EO; Taylor, AA, 2011)
"A combination of fenofibrate and niacin with low-saturated-fat D/E is effective and safe in increasing HDL-C, decreasing non-HDL-C and hypertriglyceridemia, and ameliorating hypoadiponectinemia in patients with HIV/ART-associated dyslipidemia."5.15Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. ( Balasubramanyam, A; Ballantyne, CM; Clark, P; Coraza, I; Cuevas-Sanchez, E; Giordano, TP; Iyer, D; Kamble, S; Patel, P; Pownall, HJ; Scott, LW; Sekhar, RV; Smith, EO; Taylor, AA, 2011)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Balasubramanyam, A1
Coraza, I1
Smith, EO1
Scott, LW1
Patel, P1
Iyer, D1
Taylor, AA1
Giordano, TP1
Sekhar, RV1
Clark, P1
Cuevas-Sanchez, E1
Kamble, S1
Ballantyne, CM1
Pownall, HJ1
Normén, L1
Frohlich, J1
Montaner, J1
Harris, M1
Elliott, T1
Bondy, G1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376]221 participants (Actual)Interventional2004-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

HDL-C

HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care37.1
Group 2 - Diet/Exercise Only38.7
Group 3 - Diet/Exercise + Fenofibrate40.7
Group 4 - Diet/Exercise + Niacin41.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin44.8

Non-HDL-C

non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care162.2
Group 2 - Diet/Exercise Only165.4
Group 3 - Diet/Exercise + Fenofibrate145.8
Group 4 - Diet/Exercise + Niacin154
Group 5 - Diet/Exercise + Fenofibrate + Niacin137.1

Total Cholesterol

Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care195.6
Group 2 - Diet/Exercise Only200.1
Group 3 - Diet/Exercise + Fenofibrate184
Group 4 - Diet/Exercise + Niacin190.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin178.4

Total Cholesterol : HDL-C Ratio

Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionratio (Mean)
Group 1 - Usual Care5.2
Group 2 - Diet/Exercise Only5.1
Group 3 - Diet/Exercise + Fenofibrate4.5
Group 4 - Diet/Exercise + Niacin4.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin4

Triglycerides

Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care199
Group 2 - Diet/Exercise Only216.9
Group 3 - Diet/Exercise + Fenofibrate155.1
Group 4 - Diet/Exercise + Niacin177.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin135.6

Body Composition

"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionkg (Mean)
Body cell massFat mass
Group 1 - Usual Care59.636.8
Group 2 - Diet/Exercise67.337.5
Group 3 - Diet/Exercise + Fenofibrate66.635.8
Group 4 - Diet/Exercise + Niacin67.137.7
Group 5 - Diet/Exercise + Fenofibrate + Niacin68.236.2

Insulin Sensitivity

Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionmicrograms/ml (Mean)
Fasting insulinHOMA-IRInsulin sensitvity indexAdiponectin
Group 1 - Usual Care8.71.923.547.12
Group 2 - Diet/Exercise Only6.71.384.956.04
Group 3 - Diet/Exercise + Fenofibrate9.52.023.815.24
Group 4 - Diet/Exercise + Niacin11.92.762.8811.01
Group 5 - Diet/Exercise + Fenofibrate + Niacin10.32.382.3810.34

Trials

1 trial available for fenofibrate and AIDS Seroconversion

ArticleYear
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:7

    Topics: Adiponectin; Adult; Aged; Anti-Retroviral Agents; Double-Blind Method; Dyslipidemias; Exercise; Fema

2011

Other Studies

1 other study available for fenofibrate and AIDS Seroconversion

ArticleYear
Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
    Diabetes care, 2004, Volume: 27, Issue:9

    Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Female; Fenofibrate; HIV Seropositivity

2004